CD34 and acute myeloid leukemia: In addition, we have demonstrated that ALP also has a significant impact to predict complete response, relapse or treatment resistance, and exitus, independently of variables such as age, sex, type of AML (de novo or secondary), WHO Classification of AML (2017 edition), cytogenetic and molecular alterations, ELN prognostic-risk group based on cytogenetic and molecular profile, relevant blast immunophenotyping (CD34/CD117/CD123 backbone), initial treatment, and post-remission therapy (Table 2).